

---

**INFORMATION ONLY****Update On Expanded Use of Solvent Detergent Plasma****Customer Letter # 2023-20**

---

2023-08-14

Dear Colleagues:

Further to [customer letter 2023-07](#), we wish to thank all our hospital customers who have made progress in expanding their use of Octaplasma. For those of you that have not yet started using Octaplasma, thank you for sharing your target implementation month and other feedback with your hospital liaison specialist. This information is extremely helpful as we adjust our manufacturing plan for Frozen Plasma blood component production.

**Key Date Reminder****September 30, 2023** – All hospitals should be ordering 80% or more Octaplasma by this date.

In a previous customer letter, we shared the following materials that are available from Canadian Blood Services to assist you with your implementation.

- [Frequently Asked Questions \(FAQ\)](#)
- [Solvent Detergent \(S/D treated plasma \(Octaplasma\)\)](#)

The following materials are available from Octapharma, the manufacturer of Octaplasma.

- [Octaplasma product monograph](#)
- [Octaplasma FAQ](#)

A reminder that if you have any questions related to the quality or technical specifications of Octaplasma, please contact your local Octapharma representative. Quality feedback regarding Octaplasma should be submitted to [quality.canada@octapharma.com](mailto:quality.canada@octapharma.com).

If you have questions about ordering or delivery, please contact your local Canadian Blood Services distribution site.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at [www.blood.ca](http://www.blood.ca) in the “Hospital Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Dr. Tanya Petraszko  
Senior Medical Director, Medical, Laboratory and Stem Cell Services